Art
J-GLOBAL ID:202102229497741884   Reference number:21A1630640

Quantification of [ 18 F]afatinib using PET/CT in NSCLC patients: a feasibility study

NSCLC患者におけるPET/CTを用いた[18F]アファチニブの定量:実現可能性研究【JST・京大機械翻訳】
Author (18):
Material:
Volume: 10  Issue:Page: 1-9  Publication year: 2020 
JST Material Number: U8242A  ISSN: 2191-219X  Document type: Article
Article type: 原著論文  Country of issue: United Kingdom (GBR)  Language: ENGLISH (EN)
Abstract/Point:
Abstract/Point
Japanese summary of the article(about several hundred characters).
All summary is available on JDreamIII(charged).
On J-GLOBAL, this item will be available after more than half a year after the record posted. In addtion, medical articles require to login to MyJ-GLOBAL.
Only a subgroup of non-small c...
   To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=21A1630640&from=J-GLOBAL&jstjournalNo=U8242A") }}
Thesaurus term:
Thesaurus term/Semi thesaurus term
Keywords indexed to the article.
All keywords is available on JDreamIII(charged).
On J-GLOBAL, this item will be available after more than half a year after the record posted. In addtion, medical articles require to login to MyJ-GLOBAL.

Semi thesaurus term:
Thesaurus term/Semi thesaurus term
Keywords indexed to the article.
All keywords is available on JDreamIII(charged).
On J-GLOBAL, this item will be available after more than half a year after the record posted. In addtion, medical articles require to login to MyJ-GLOBAL.
, 【Automatic Indexing@JST】
JST classification (1):
JST classification
Category name(code) classified by JST.
Tumors(=neoplasms)of respiratory system 
Reference (21):
  • CA Cancer J Clin; Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries; F Bray, J Ferlay, I Soerjomataram, RL Siegel, LA Torre, A Jemal; 68; 6; 2018; 394-424; 10.3322/caac.21492; citation_id=CR1
  • Ann Oncol; European cancer mortality predictions for the year 2017, with focus on lung cancer; M Malvezzi, G Carioli, P Bertuccio, P Boffetta, F Levi, C Vecchia; 28; 5; 2017; 1117-1123; 10.1093/annonc/mdx033; citation_id=CR2
  • CA Cancer J Clin; Cancer statistics, 2019; RL Siegel, KD Miller, A Jemal; 69; 1; 2019; 7-34; 10.3322/caac.21551; citation_id=CR3
  • Science.; EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy; JG Paez, PA Janne, JC Lee, S Tracy, H Greulich, S Gabriel; 304; 5676; 2004; 1497-1500; 10.1126/science.1099314; citation_id=CR4
  • Lancet Oncol; Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial; R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip; 13; 3; 2012; 239-246; 10.1016/S1470-2045(11)70393-X; citation_id=CR5
more...

Return to Previous Page